Neuropathic Pain Clinical Trial
Official title:
Efficacy of Percutaneous Electrical Nerve Stimulation Compared With Passive Assisted Neurodynamics in Brachial Plexus Neuropathy: a Pilot Randomized Controlled Trial.
Brachial plexus neuropathies, specifically of the median, radial, ulnar, suprascapular, axillary and dorsal scapular nerves, can arise when a peripheral nerve trunk or nerve root is subjected to injury, compression, inflammation or ischemia, resulting in reduced physical capabilities of the peripheral nervous system. Although pharmacological treatments provide mild symptomatic relief in the short term, they are not without side effects. Neurostimulation techniques may be an effective treatment option for peripheral brachial plexus neuropathies. Some of these procedures are transcutaneous electrical nerve stimulation (TENS) or percutaneous electrical nerve stimulation (PENS). Although some case series have documented a positive effect in relation to ultrasound-guided PENS for subjects with subacromial pain syndrome or postsurgical pain, the lack of studies, to our knowledge, analyzing the effects of percutaneous electrical nerve stimulation, in relation to pain and paresthesias in subjects with brachial plexus neuropathy, warrants investigation for this goal.
Status | Recruiting |
Enrollment | 11 |
Est. completion date | January 1, 2023 |
Est. primary completion date | December 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Subjects with upper limb neural symptomatology between 18 and 60 years of age, presenting two or more of the following conditions: - Paresthesias in any territory of the shoulder girdle, arm or hand - Pain at rest in any territory of the upper extremity. - Pain at rest in any upper extremity territory - Sensations of electric shock in any territory of the shoulder girdle, arm or hand. - Allodynia or cutaneous hyperalgesia in any territory of the shoulder girdle, arm or hand. Exclusion Criteria: - Less than 2 weeks of evolution - Fracture in the affected upper extremity - Suffering from another joint disorder such as osteoarthritis or rheumatic disease - Suffering from generalized neuropathies due to neuromuscular disease or medication - Inability to understand instructions or sign informed consent. - Wearing a pacemaker or any electrical device implanted in the body - Epilepsy - Aversion or fear of needles - Pregnant. |
Country | Name | City | State |
---|---|---|---|
Spain | Physiotherapy and exercise center Origenkinesis | Alcorcón | Madrid |
Lead Sponsor | Collaborator |
---|---|
Universidad Rey Juan Carlos |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Lanss Scale | Useful to identify patients with a pain experience dominated by neuropathic mechanisms. It is based on the analysis of sensory description and exploration of sensory dysfunction at the patient's bedside. It consists of 7 items and is scored from 0 to 24. At a score of less than 12, the neuropathic component is considered unlikely. A score greater than or equal to 12 is considered probable neuropathic pain. It is a validated scale for patients with neuropathic pain. | 10 minutes | |
Primary | Pain Detect Scale | Screening questionnaire for neuropathic pain. This scale consists of a section dedicated to pain intensity and another that is responsible for assessing the qualitative aspect of pain, i.e., identifying whether the pain is of neuropathic characteristics. In the total of this scale the maximum possible score is 38 points and the minimum -1. For screening purposes, a score less than or equal to 12 is considered an unlikely neuropathic component. A score greater than or equal to 19 concludes that the neurological component in pain is probable. | 10 minutes | |
Primary | Numerical Pain Rating Scale (NPRS) | A unique 11-point numerical scale validated in patients with various painful conditions. Data obtained through NPRS are easily documented, intuitively interpretable, and meet regulatory requirements for pain assessment and documentation. This scale is reliable and validated for assessing patients with pain20. Score 0 corresponds to "no pain" and score 10 corresponds to "maximum possible pain". In this study, patients were asked to mark their maximum pain detected in the last week (NPRS Max) and their minimum pain detected in the last week (NPRS Min). | 1 minute | |
Secondary | Neural stress test | Nerves react to certain mechanical stresses and forces, but to establish positivity of such tests, the possibilities of "false positivity" due to other non-nerve structures must first be eliminated. The determination of a positive neural test is established by provocation and symptom relief techniques. In this outcome measure only a positive or negative test was considered. The test was positive if the patient's neural symptoms were reproduced during provocation, or negative if no such symptoms occurred. | 5 minutes | |
Secondary | DASH scale | It is a validated scale for assessing upper limb functionality. It is an instrument that can be completed by the patient with the help of the physical therapist. It consists of 30 questions that assess certain symptoms, as well as the ability to perform activities, ranging from 1 to 5, with 1=no difficulty and 5=maximum difficulty. The higher the score, the greater the upper limb disability. | 5 minutes | |
Secondary | Thermography | A thermal camera, HT-02D infrared thermographic and visible light camera with IR 1024 pixels and -20~300°C, 6Hz refresh rate, infrared thermometer was used. The thermograph indicates the approximate temperature of the body segment to be examined by focusing it with the thermographic camera. | 10 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04699734 -
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Completed |
NCT05235191 -
Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies
|
Phase 3 | |
Completed |
NCT05845177 -
Persistent Pain After Hip Replacement
|
||
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05949554 -
Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
|
||
Withdrawn |
NCT05052645 -
Ear Acupuncture for Neuropathic Pain
|
N/A | |
Completed |
NCT02824588 -
Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain
|
N/A | |
Completed |
NCT02866396 -
Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
|
||
Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
Active, not recruiting |
NCT02560545 -
Cannabinoids Effects on the Pain Modulation System
|
N/A | |
Enrolling by invitation |
NCT02485795 -
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management
|
N/A | |
Not yet recruiting |
NCT02246517 -
The Effect of N2O on Chronic Neuropathic Pain Patients
|
Phase 0 | |
Completed |
NCT02099890 -
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Completed |
NCT01718821 -
Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients
|
N/A | |
Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
Completed |
NCT01669967 -
The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin
|
N/A | |
Completed |
NCT01201317 -
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
|
Phase 2 | |
Completed |
NCT01207596 -
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain
|
Phase 4 |